获批1类创新药的持有人可获最高1500万元省级财政支持

Core Viewpoint - The newly issued "Policy Measures" by Sichuan Province aims to enhance the high-quality development of the biopharmaceutical and medical device industries through 21 initiatives covering the entire R&D to application chain, addressing challenges such as long R&D cycles and slow market access [1][2]. Group 1: Financial Support and Incentives - Financial support includes up to 15 million yuan for each approved Class 1 innovative drug based on different clinical trial stages, and a maximum subsidy of 2 million yuan for approved national and provincial innovative medical devices [1][3]. - The policy encourages the establishment of collaborative R&D platforms among universities, research institutions, and enterprises, and supports the inclusion of eligible clinical trials and transformation projects into provincial science and technology plans [2]. Group 2: Regulatory and Approval Process Improvements - The review time for innovative drugs will be reduced from 200 working days to 60 working days, while the technical review time for Class II medical devices will be shortened to 35 working days [1][3]. - The policy integrates the volume of clinical trials into the annual assessment of clinical medical research centers, providing incentives for hospitals that demonstrate effective application of innovative drugs and devices [2]. Group 3: Ecosystem Development - Sichuan Province aims to strengthen financial support, enhance intellectual property protection, and build a skilled workforce to create a favorable ecosystem for industry development [2].